{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001771","form_type":"8-K/A","ticker":null,"cik":"0001662244","company_name":"Cyteir Therapeutics, Inc.","filed_at":"2023-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.052275+00:00","generated_at":"2026-06-20T01:09:13.449197+00:00","sec_items":["2.02","2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cyteir cuts 70% of workforce, focuses CYT-0851 on ovarian cancer; cash runway to 2026","bullets":["Workforce reduced by ~70% to 15 or fewer employees; expects $2.5M-$3M severance charges in Q1 2023.","CEO Markus Renschler eligible for retention bonus of 150% of target annual bonus if employed through Dec 31, 2023.","CBO Andrew Gengos separating Feb 3, 2023; CSO Paul Secrist separating Apr 1, 2023; stock options accelerated.","Phase 2 monotherapy enrollment suspended; focus on CYT-0851 + capecitabine for platinum-resistant ovarian cancer.","Cash and cash equivalents $147M as of Dec 31, 2022 (unaudited); estimated cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001771","json":"https://secwatch.observer/filing/0000950170-23-001771.json","markdown":"https://secwatch.observer/filing/0000950170-23-001771.md","text":"https://secwatch.observer/filing/0000950170-23-001771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/cyt-20230112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:09:13.449197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51fdc4c7a1","claim":"Andrew Gengos departed as Chief Business Officer at Cyteir Therapeutics, Inc..","evidence_excerpt":"Andrew Gengos, the Company’s Chief Business Officer will separate from the Company effective February 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"e4fa9bc08e","claim":"Paul Secrist departed as Chief Scientific Officer at Cyteir Therapeutics, Inc..","evidence_excerpt":"Paul Secrist, Ph.D., the Company’s Chief Scientific Officer will separate from the Company effective April 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"cc4e23edb35bd3691e1a6bef5755dd48e8ad1b90","claim":"Cyteir Therapeutics, Inc. announced a restructuring with charges of $2.5 million to $3 million (approximately 70% of the Company’s workforce).","evidence_excerpt":"the Company expects to have 15 or fewer full-time employees. The Company estimates that, in connection with these changes, it will incur aggregate charges of approximately $2.5 million to $3 million, all of which are anticipated to result in future cash expenditures, primarily for one-time employee severance and benefit costs, the majority of which are expected","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$2.5 million to $3 million"},{"label":"Headcount","value":"approximately 70% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}